Accelerate Diagnostics reports Q4 net loss $13M, full-year net loss $61.6M; Wave trials planned Q2 2024

Accelerate Diagnostics, Inc

Q4 net sales $3.0M flat YoY; full-year net sales $12.1M down 5% from $12.8M.
Q4 gross margin 21% vs 28% YoY; full-year 21% vs 26%, including $1.2M inventory write-down.
Q4 net loss $13.0M ($0.89/share); full-year net loss $61.6M ($4.94/share).
Cash used Q4 $7.9M, full-year $46.3M; year-end cash $13.2M.
Wave AST system clinical trials on track for Q2 2024; ~90% customer interest in adoption.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Accelerate Diagnostics, Inc reported financial results for the quarter and full-year ending December 31, 2023.

Period: the quarter and full-year ending December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Accelerate Diagnostics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full-year ending December 31, 2023

View on SEC.gov

324 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-041230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.